NDC 0591-3365 - Lorazepam
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0591-3365
- Package NDCs from labels
- 0591-3365-54, 0591-3365-45, 0591-3365-79, 0591-3365-70
- Manufacturer
- Watson Laboratories, Inc.
- Effective date
- 2006-06-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| LORAZEPAM INJECTION USP C-IV Rx only | Watson Laboratories, Inc. | 2006-06-14 | HUMAN PRESCRIPTION DRUG LABELING |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Lorazepam | ACTIVE INGREDIENT | O26FZP769L | LORAZEPAM (LORAZEPAM) INJECTION [WATSON LABORATORIES, INC.] | 1 | |
| Lorazepam | ACTIVE MOIETY | O26FZP769L | LORAZEPAM (LORAZEPAM) INJECTION [WATSON LABORATORIES, INC.] | 1 | |
| Benzyl Alcohol | INACTIVE INGREDIENT | LKG8494WBH | LORAZEPAM (LORAZEPAM) INJECTION [WATSON LABORATORIES, INC.] | 1 | |
| Polyethylene Glycol 400 | INACTIVE INGREDIENT | LORAZEPAM (LORAZEPAM) INJECTION [WATSON LABORATORIES, INC.] | 1 | ||
| Propylene Glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | LORAZEPAM (LORAZEPAM) INJECTION [WATSON LABORATORIES, INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| AE274B1F-27C3-483B-99F1-9A9249DC2459 | AE274B1F-27C3-483B-99F1-9A9249DC2459 | 2006-06-14 | Warnings, Adverse reactions | AE274B1F-27C3-483B-99F1-9A9249DC2459 AE274B1F-27C3-483B-99F1-9A9249DC2459 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.